Despite the initial optimism, BMO urged caution, emphasizing that the advantage may be short-lived. The firm said Eli Lilly’s ...

Novo Nordisk's Frankfurt-listed shares opened nearly 10% higher in early trading on Tuesday after the U.S. Food and Drug ...

Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.

Novo Nordisk's shares surged nearly 10% after the FDA approved its weight-loss pill, granting it an advantage over Eli Lilly.

Investing.com -- Novo Nordisk’s (CSE:NOVOb) long-awaited entry into the obesity pill market lifted investor sentiment, with the stock jumping more than 7% on Tuesday, though analysts at BMO Capital ...

Novo Nordisk AS won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its ...

Canada's main stock index rose to another record high on Monday as soaring precious metal prices fed optimism the index's ...

The 12,429 fans who withstood rain, freezing temperatures and a 40-minute lightning delay all recognized the magnitude of the ...

Lorenzo Insigne is edging closer to a return to Serie A, with Lazio preparing a short-term contract to bring the former ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

“I think time is running out,” he said. “We’re not in the 10th inning anymore, we’re in the 13th or 14th.” In December, the ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...